Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss
- 23 April 2016
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 18 (6) , 1-10
Abstract
Advances in oncologic therapies have led to considerable improvements in prognosis and survival. However, these improvements may ultimately be diminished by the increase of cardiovascular side effects. Typically, both conventional and new antitumoral therapies may induce asymptomatic or symptomatic left ventricular dysfunction. Its development still remains a major deterrent that may compromise clinical effectiveness of cancer treatment, independently of the oncologic prognosis, having a serious impact on the patient’s survival and quality of life. Hence, prevention of cardiotoxicity remains a crucial topic both for cardiologists and oncologists. Many strategies to mitigate the risk of cardiotoxicity have been developed, including cardiac function monitoring, limitation of chemotherapy doses, use of anthracycline analogues and cardioprotectants, and early detection of cardiotoxicity by biomarkers, followed by prophylactic intervention in selected high risk patients. We reviewed the currently available approaches which have been demonstrated to be effective in preventing or limiting cancer drug-induced cardiotoxicity.Keywords
This publication has 61 references indexed in Scilit:
- Late Cardiac Effects of Cancer TreatmentJournal of Clinical Oncology, 2012
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2012
- Exercise interventions on health-related quality of life for people with cancer during active treatmentCochrane Database of Systematic Reviews, 2012
- Modulation of Anthracycline-Induced Cardiotoxicity by Aerobic Exercise in Breast CancerCirculation, 2011
- Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell FunctionCirculation, 2010
- Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological PreventionJNCI: Journal of the National Cancer Institute, 2010
- American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late EffectsJournal of Clinical Oncology, 2007
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategiesBritish Journal of Haematology, 2005
- Potential protective role of angiotensin‐converting enzyme inhibitors captopril and enalapril against adriamycin‐induced acute cardiac and hepatic toxicity in ratsJournal of Applied Toxicology, 2001